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I N THE transplant populations and patients with autoim-
mune diseases, the quality of liver function signifi-
cantly influences FK 506 doses, drug trough plasma levels, 
and kidney function. The interrelationship of these varia-
bles has been previously discussed in patients with dif-
ferent kinds of organ transplantation. 1 In this report, 
however, we will concentrate only on liver recipients with 
different degrees of graft dysfunction, particularly in the 
perioperative period. From this study, a better understand-
ing has been achieved of FK 506 management strategy in 
patients with variable quality of liver function. 
MATERIALS AND METHODS 
Patient Population 
Forty-nine adults who were 17 to 69 years old (47 :t 15) received 
liver transplantation between Dec 16, 1989. and May 5. 1990. 
Liver transplantation was primary in all patients and FK 506 was 
the standard immunosuppressive agent. Twenty·three were males 
and 26 were females. The principal inclusion criterion was suffi-
cient FK 506 plasma trough determinations to permit a reasonably 
complete reconstruction of events for the first 60 days after 
transplantation. Cases were excluded if a technically Hawed 
operation was performed or if the patient previously received 
cyclosporine (CyA). 
Patients were stratified into four postoperative categories based 
on the quality of liver graft function and to a lesser degree on the 
rapidity of recovery from intensive care support. The pre trans-
plant features of all classes are shown in Table I. Class I patients 
(n = 14) became jaundice free with bilirubins less than 2 mg % by 
10 days after surgery. They also did not have evidence of major 
graft ischemia and were ventilator independent within 3 days. 
Class II cases (n = 17) had less perfect biochemical liver function 
tests. particularly in the first 5 days, but recovery thereafter was 
rapid. Five of these patients required ventilator assistance beyond 
3 days. Class III (n = 10) and class IV (n = 8) patients had 
dysfunctional liver grafts with bilirubins above 2 mg % beyond 10 
days in class III and throughout the 2-month period of study in 
class IV individuals. All class III and IV patients required pro-
longed ventilatory support and total parenteral nutrition. 
All included patients were free of intrinsic chronic renal dis-
ease. However, at the time of transplantation. II patients (22.4%) 
had hepatorenal syndro~e with requirement for pre transplant 
dialysis in 4 (8.2%). Death due to multiple-organ failure and sepsis 
occurred in two class IV patients during the study period. giving 
a total survival rate of 95%. 
Immunosuppression 
FK 506 therapy began in most patients 2 to 3 hours after 
revascularization of the graft. It was given initially intravenously 
in a dose of 0.075 mg/kg to be infused over 4 hours and repeated 
every 12 hours until oral administration was started. This intra-
venous (IV) dose is at least 50% greater than the starting IV dose 
now being recommended. When the conversion was made from 
IV to oral dosing at 0.15 mg/kg/12 h. administration by both routes 
frequently was overlapped for one or two doses. The beginning 
oral dose is the same as that used currently. 
Graft biopsies were obtained after 10 to 14 days or before this if 
there was evidence of graft dysfunction. Dose adjustments were 
made in most patients on clinical grounds since plasma trough 
levels of FK 506 were not available until several days later. 
Revisions of the doses were dictated by suspected adverse effects 
of FK 506. of which renal and neurologic dysfunction were the 
most common. Increases iii serum creatinine above 2 mg %, BUN 
above 60 mg %, and changes in the mental status concomitant 
with significant tremors were the warning parameters for dose 
reduction, especially if there was significant graft dysfunction. In 
addition. clinical and/or bacteriological documentation of sepsis 
was an incentive to temporarily reduce the FK 506 dose. Upward 
dose adjustments were prompted by a clinical. biochemical. 
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Table 1. Characteristics of All Uver Recipients 
Sex PreoperatiVe Biochemical Data 
Total Age Bilirubin SGPT BUN Creatinine Pre-OLTx 
Class No. (Mean::!: SO) Male Female (mg%) (lUll) (mg%) (mg%) DIalysis 
14 44:t 17 4 10 6.7:t 7 103:t 89 17:t 8 0.9:t 0.4 o (0"10) 
II 17 49 = 10 9 8 11.1=12 106:t 115 23:t 15 1.1 :t 0.5 1 (6%) 
III 10 45:t 16 5 5 10.2 = 8 35:t 20 39:t 33 1.7:t 1.3 1 (10"10) 
IV 8 50 :t 15 5 3 21 :t 12 280:t 338 46:t 27 2.7:t 1.4 2 (25%) 
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and/or histopathological diagnosis of graft rejection. or sometimes 
by persistent low plasma FK 506 levels. 
Steroid therapy usually was started at a daily dose of 20 mg, but 
in a number of the early patients a 5-day steroid cycle was used, 
starting at 200 mg (four divided doses) and finishing at 20 mg/d. By 
the end of the 60 postoperative days, 27 (55%) of the patients were 
completely weaned from steroids. The degree and rate of dose 
reduction was dictated by the functional status of the graft, biopsy 
results, evidence of ongoing sepsis, and toxicity from either the 
FK 506 or the steroids. 
The rejection episodes were treated first with an increase in FK 
506 doses if this was pennitted by the state of the renal function. 
Steroid boluses with increase in the daily maintenance dose were 
given to patients with persistent rejection as evidenced by unsat-
isfactory biochemical and/or histological response. Steroid resis· 
tant rejection that required a 3- to 5-day course of OKT3 devel-
oped in 9 recipients (18.4%). 
FK 506 Plasma Levels 
Trough plasma FK 506 levels were determined with the enzyme 
immunoassay technique of Tamura et al~ in samples obtained 
twice per week or more often in complicated cases. However, 
results from the plasma determinations did not inftuence the 
immediate management decision because they were not available 
until several days later. The optimal 12-hour trough levels were 
thought to be in the 0.5 to 1.5 ng/mL range. In most of the patients 
with good graft functions (classes I and II), these trough values 
were in 12-hour samples, However, in several of the class III or 
IV patients, FK 506 was given once per day or every other day 
and consequently the so-called troughs were measured 24 to 48 
hours after the last dose. 
Statistical Analysis 
The 6O-day study period was divided into 5-day intervals. For 
each such interval in each patient, the mean value for all variables 
was obtained. These means were pooled for all patients in the four 
classes and the means (:!:SE) were calculated. Single-variable 
comparison between two or more of the classes at each time point 
was done by unpaired Student's t test and Bonferroni's (Dunn) 
test, respectively. Signed rank comparisons with Bonferroni ad-
justment were utilized for serial analysis of changes in each 
parameter at all times of the study period and Kendall tau test for 
the correlation between two variables with and without a lag time. 
These were computed using SASIPC version 6.03 (SAS Institute, 
Inc, Cary, NC). 
RESULTS 
Liver Graft Function 
During the 6O-day study period, serum bilirubin was sig-
nificantly higher in class IV cases compared to classes I 
and II. Although the patients in classes III and IV were 
considered catastrophic with the need for tracheostomy 
and ventilator dependence for many weeks or months in 12 
of the 18 patients. 16 of them survived. The only deaths 
were from multiple-organ failure at 40 and 47 days in 2 
class IV patients. There were no deaths or graft losses 
among class I. II. or III patients. 
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FK 506 Plasma Levels and Drug Doses 
In class IV patients. plasma FK 506 levels were astonish-
ingly high for most of the first month and up to 60 days. 
Although the same starting IV doses of FK 506 were used 
for all patients. the drug plasma trough levels were dif-
ferent in the four recovery classes (Fig 1), In class IV 
patients, FK 506 plasma levels were significantly higher (P 
= .0001) than that of class I. II. and III patients at all study 
points. 
The doses of FK 506 were reduced in most of the 
patients within the first 10 days after transplantation. In 
class IV patients, the period of IV administration of FK 
506 was more prolonged and the acutely reduced dose was 
significantly lower than in classes I. II. and III. However. 
by the end of the first 30 postoperative days there was no 
significant difference in FK 506 doses comparing the four 
classes. At that time, graft functions were similar for all 
classes except class IV. 
Kidney Function 
Daily serum creatinine and blood urea nitrogen <B UN) 
measurements were used to monitor changes in renal 
function. Both parameters were significantly elevated at all 
points of the 60-day study period. In class I and II patients, 
the maximal increase in serum creatinine occurred 2 to 3 
days after the FK 506 plasma level reached its peale In the 
undialysed patients, early postoperative serum creatinine 
and BUN changes were significantly higher in class III and 
IV patients compared to classes I and II. 
There was no new perioperative dialysis requirement in 
the class I and II recipients and. in fact. a previously 
dialysis-bound patient in class II had restoration of renal 
function 21 days after transplant. Renal failure severe 
enough to require dialysis for the first time was common in 
classes III (n = 4 of lO) and IV (n = 5 of 8). although this 
was reversible in most of the cases (Fig 1). At the end of60 
days, five patients were still on dialysis. Four of these five 
have subsequently recovered from renal failure. leaving 
only one patient, who died 6 months later of respiratory 
failure. 
Correlation Analyses 
Bilirubin, FK 506 Doses. and Drug Plasma Levels. The 
correlations of serum bilirubin. plasma FK 506 levels 
drawn on the same day, and the drug dose given are shown 
in Fig 2 for patients of the combined classes I through IV. 
There was a significant linear correlation between serum 
bilirubin (P = .0001) and plasma FK 506 level despite an 
inverse correlation with FK 506 doses (P = .001). There 
was also a significant linear correlation between the doses 
and plasma levels of FK 506. These correlations were 
especially sharp when patients of class I were compared 
with those of class IV. 
FK 506 Plasma Levels and Serum Creatinine. There 
was no statistically significant correlation between serum 
creatinine and FK 506 plasma levels in the patients who 
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did vs those who did not require dialysis. However. the 
mean FK 506 plasma levels were significantly (P < .05) 
higher in patients who required hemodialysis than that of 
the patients who maintained adequate kidney function. 
Steroid Therapy 
The maintenance steroid dose was more significantly re-
duced (P < .05) in class IV patients compared to the other 
classes. particularly in the earty postoperative period. The 
early graft dysfunction with the coexistence of life-threat-
ening sepsis dictated the early reduction of steroid doses in 
many of these cases. By the end of 20 days. there was no 
significant difference in the mean steroid doses for the four 
classes. Collectively, 55% of these patients (n = 27) were 
weaned from steroids at the end of the 6O-day study 
period. 
DISCUSSION 
The pharmacokinetics of the new immunosuppressive 
drug FK 506 are reasonably well understood in large 
animals and humans.3.4 FK 506 is metabolized mainly by 
the liver and its terminal half-life after a redistribution 
phase is about 9 hours.3 The drug clearance, however. is 
high and actually exceeds total hepatic blood flow. indi-
Fig 1. Effect of postoperative 
liver function on FK 506 doses . 
plasma levels. and kidney func-
tion. Note that the highest plas-
ma levels despite the lowest 
doses were in the patients with 
earty unsatisfactory graft func-
tion. Meanwhile. four class III pa-
tients and five class IV patients 
required postoperative dialysis 
for some time. 
eating significant extrahepatic metabolic pathways. In con-
trast, the clearance rate of Cy A is low. S Also. the nature of 
oral FK 506 absorption and timing of peak plasma levels 
appear to differ from CyA. In contrast to CyA, FK 506 
does not need bile to be absorbed from the gastrointestinal 
tract.6 The oral formulation of FK 506 also seems to have 
"slow release" qualities with blunted peak plasma levels 
and modest fluctuations in plasma concentrations. 
Although there has been no evidence of hepatic or 
cardiac toxicity in different organ recipients, it is clear that 
liver function influences all postoperative pharmacokinetic 
variables. In patients with relatively normal liver graft 
function (class I) and those with significantly damaged but 
quickly recovered grafts (class II), t~e starting IV and oral 
doses were well tolerated. Plasma FK 506 trough levels 
rose during IV administration, but the levels quickly 
receded once oral dosing was started. Since FK 506 
augments liver regeneration, its presence actually may 
have facilitated recovery of the graft from perioperative 
ischemic damage. 7 •s 
In class III and IV patients with significant perioperative 
graft dysfunction. the plasma FK 506 levels rose astronom-
ically and stayed high for several days in spite of dose 
reduction or even discontinuance. This was most evident 
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Fig 2. Scatter plots for the actual values of simultaneously 
determined serum bilirubin. FK 506 plasma level. and drug dose 
on log10 scale for all recipients. Serum bilirubin has a significant 
positive correlation with FK 506 plasma levels and inverse corre-
lation with FK 506 doses. With r value of 0.158. there was a 
significant (P = .0007) correlation between FK 506 doses and 
levels. 
during the period of FK 506 IV therapy. The high levels 
appeared to be associated with a high incidence of dialysis. 
Increases in renal function indices were noticed 2 to 3 days 
following the high peaks of FK 506 plasma levels. Clearly. 
FK 506 was not the only nephrotoxic factor. Most of these 
class III and IV patients had variable degrees of multiple-
organ failure before transplantation or perioperatively. 
Hypotension, sepsis. and the need for nephrotoxic antibi-
otics were almost invariable. These are known to be 
independent or collaborating factors in the development of 
renal failure following liver transplantation, no matter 
what the drug therapy.9.!O 
However, the nephrotoxic effect of FK 506 could be 
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clearly analyzed in class I and II patients who did not have 
significant liver graft dysfunction or coexistent systemic 
sepsis. The temporary rises in plasma FK 506 levels during 
IV therapy and the concomitant rises in BUN and creati-
nine were partly reversed when the FK 506 doses were 
lowered or changed to the oral route. In these patients. the 
deterioration in renal function did not correlate signifi-
cantly with plasma FK 506 levels. Yet. dose reduction of 
FK 506 appeared to be a beneficial adjustment. 
This study. which has been reported earlier in greater 
detail.I.!! has led to inescapable conclusions. First, pa-
tients with defective drug metabolism caused by hepatic 
dysfunction are more vulnerable to acute or prolonged 
overdose of FK 506, toxic blood levels of FK 506. and the 
development of renal dysfunction. Second, the IV FK 506 
doses used in these early trials were too high, even for 
patients with good liver graft function. Our current prac-
tice is to give IV FK 506 by constant infusion at a dose of 
0.1 mglkgld or even lower instead of the 4-hour bolus 
infusion twice a day used in this study. In contrast, the oral 
doses every 12 hours were appropriate if good graft 
function was achieved. 
With either IV or oral dosing, the demonstration that FK 
506 kinetics are markedly affected by hepatic dysfunction 
is a clear warning against overdosage in patients with 
failing liver grafts under primary FK 506 therapy or in 
those under conventional immunosuppressive therapy 
who are switched to FK 506. Failure to frequently monitor 
plasma FK 506 levels in these patients with quick and 
appropriate dose adjustments can lead to serious drug 
toxicity. 
REFERENCES 
I. Abu-E1magd K. Fung JJ. A1essiani M. et a1: Transplantation 
52:71, 1991 
2. Tamura K. Kobayashi M. Hashimoto K. et al: Transplant 
Proc 19(suppl):23. 1987 
3. Venkataramanan R. Jain A. Cadoff E. et al: Transplant Proc 
22:52,1990 
4. Jain AB. Venkataramanan R. Cadoff E. et al: Transplant 
Proc 22:57. 1990 
5. Ptachcinski RJ, Venkataramanan R. Burckard GJ: Clin 
Phannacokinet II: 107. 1986 
6. FiJrukawa H. lmventarza O. Venkataramanan R. et al: 
Transplantation (in press) 
7. FrancavillaA. Barone M. Todo S. etal: Lancet 1:1248, 1989 
8. Stanl TE. Porter KA. Mazzaferro V. et al: Transplantation 
51 :67, 1991' 
9. McCauley J. Van Thiel D. Starzi TE. et al: Nephron 55: 121. 
1990 
10. McCauley J, Fung JJ, Jain A. et al: Transplant Proc 22:17. 
1990 
11. Starzl TE. Abu-Elmagd K. Tzakis A. et al: Transplant Proc 
23:914, 1991 
